MENU
Alnylam Clinical Trials Alnylam Clinical Trials

Alnylam Clinical Trials

Visit www.clinicaltrials.gov for more information on all of Alnylam’s clinical trials.




For more information, and to speak to someone from our team, please contact us:
Alnylam Clinical Trial Information Line
866-330-0326 (Toll-free within the U.S.)
+1 617-575-7400 (International)
clinicaltrials@alnylam.com
Clear Filter [x]

Filter By:

Disease
  • Familial Amyloidotic Polyneuropathy (FAP)
  • Familial Amyloidotic Cardiomyopathy (FAC)
  • Hemophilia
  • Hepatic Porphyria
  • Complement-Mediated Diseases
  • Hypercholesterolemia
  • Alpha-1 Antitrypsin Deficiency
  • Primary Hyperoxaluria
Study Phase
  • Observational
  • Development
  • Phase 1
  • Phase 2
  • Phase 3
Status
  • Enrolling
  • Enrollment Complete
  • Active, Not Recruiting
  • Completed
Disease Study Phase Learn More Status
ATTR Amyloidosis with Polyneuropathy (also known as Familial Amyloidotic Polyneuropathy (FAP))
Phase 3 APOLLO Study
Studying patisiran (ALN-TTR02) in adults with ATTR Amyloidosis with Polyneuropathy (also known as Familial Amyloidotic Polyneuropathy (FAP)
APOLLOtrial.com enrollment complete
Enrollment Complete
ATTR Amyloidosis with Cardiomyopathy (also known as Familial Amyloidotic Cardiomyopathy (FAC))
Phase 3 ENDEAVOUR Study
Studying revusiran (ALN-TTRsc) in adults with ATTR Amyloidosis with Cardiomyopathy (also known as Familial Amyloidotic Cardiomyopathy (FAC)
Discontinued
ATTR Amyloidosis with Cardiomyopathy (also known as Familial Amyloidotic Cardiomyopathy (FAC))
DISCOVERY Observational Study
Examining the prevalence of TTR mutations in adults suspected of having cardiac amyloidosis
enrollment complete
Enrollment Complete
Hemophilia A & B
Phase 1 Study
Study of ALN-AT3 for the treatment of hemophilia A & hemophilia B
ClinicalTrials.gov enrolling
Enrolling
Acute Intermittent Porphyria (AIP)
Phase 1 Study
Study of ALN-AS1 for the treatment of Acute Intermittent Porphyria (AIP)
ClinicalTrials.gov enrolling
Enrolling
Hepatic Porphyrias
EXPLORE Natural History Study
A prospective observational study of patients with hepatic porphyrias, including acute intermittent porphyria (AIP), variegate porphyria, and hereditary coproporphyria, suffering from recurrent attacks
ClinicalTrials.gov active, not recruiting
Active, Not Recruiting
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1/2 Study
Study of ALN-CC5 for the treatment of paroxysmal nocturnal hemoglobinuria
ClinicalTrials.gov active, not recruiting
Active, Not Recruiting
Hypercholesterolemia
Phase 1 Study
Study of ALN-PCSSC for the treatment of elevated low density lipoprotein cholesterol (LDL-C)
ClinicalTrials.gov completed
Completed
Alpha-1 Antitrypsin Deficiency
Phase 1/2 Study
Study of ALN-AAT for the treatment of ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
ClinicalTrials.gov active, not recruiting
Active, Not Recruiting
Primary Hyperoxaluria
Phase 1/2 Study
Study of ALN-GO1 for the treatment of primary hyperoxaluria type 1 (PH1).
ClinicalTrials.gov enrolling
Enrolling
ATTR Amyloidosis with Polyneuropathy (also known as Familial Amyloidotic Polyneuropathy (FAP))
Phase 2 Open Label Extension Study
Study of patisiran in adults with FAP who participated in the Phase 2 trial
ClinicalTrials.gov active, not recruiting
Active, Not Recruiting
ATTR Amyloidosis with Cardiomyopathy (also known as Familial Amyloidotic Cardiomyopathy (FAC))
Phase 2 Open Label Extension Study
Study of revusiran (ALN-TTRsc) in adults with FAC who participated in the Phase 2 trial
ClinicalTrials.gov active, not recruiting
Active, Not Recruiting
ATTR Amyloidosis with Polyneuropathy (also known as Familial Amyloidotic Polyneuropathy (FAP))
Phase 2 Study
Study patisiran (ALN-TTR02) in adults with FAP
ClinicalTrials.gov completed
Completed
ATTR Amyloidosis with Cardiomyopathy (also known as Familial Amyloidotic Cardiomyopathy (FAC))
Phase 2 Study
Study of Revusiran (ALN-TTRSC)in adults with FAC
ClinicalTrials.gov completed
Completed

Additional Programs in Development

If you’re interested in learning more about our other programs in development, please click on the links below.

Genetic Medicines Cardio-Metabolic Diseases Hepatic Infectious Diseases
  • Primary Hyperoxaluria
  • Hyperlipidemia
  • Hepatitis B Virus
  • Hepatitis D Virus
  • Chronic Liver Infection